ZANAMIVIR MICRONIZED - search results

Ireland - English - HPRA (Health Products Regulatory Authority)

relenza 5mg/dose, inhalation powder, pre-dispensed

glaxosmithkline (ireland) limited - zanamivir - inhalation powder, pre-dispensed - 5 milligram(s)/dose - zanamivir

relenza 5mg/dose, inhalation powder, pre-dispensed

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - zanamivir - inhalation powder, pre-dispensed - zanamivir 5 µg/dose - antivirals for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

relenza rotadisk

glaxosmithkline nz limited - zanamivir 5mg (micronised); - powder for inhalation - 5 mg - active: zanamivir 5mg (micronised) excipient: lactose monohydrate - treatment of influenza: relenza is indicated for treatment of both influenza a and b in adults and children (5 years or older) who present with symptoms typical of influenza when influenza is circulating in the community. prophylaxis of influenza: vaccination remains the primary method of preventing and controlling influenza. relenza is indicated for prophylaxis of influenza a and b in adults and children (5 years or older) to reduce transmission among individuals in households with an infected person. relenza is indicated for prophylaxis of influenza a and b during community outbreaks only in circumstances where such prophylaxis is justified (such as when vaccine that antigenically matches circulating influenza is not available or there is a pandemic). it is not recommended for routine prophylaxis against influenza infection.